Is palbociclib/palbociclib a targeted drug? Belong to several generations

Palbociclib/Pabociclib is a cancer-targeted drug. It is also known as Ibrance. Palbociclibbelongs to the third generation cyclin-dependent kinase inhibitors (CDKis), an established treatment class for advanced and metastatic breast cancer. It has been reported that there are individual differences in the treatment response to CDKis, and some individuals may experience increased toxicity and unexpected events.

Compared with traditional chemotherapy drugs, palbociclib has better safety and tolerability. It is widely used in the treatment of breast cancer, especially in patients with hormone receptor-positive, HER2-negative advanced breast cancer. Doctors may treat you with palbociclib if your breast cancer has spread to the area and structures around the breast, such as nearby lymph nodes, muscles, and skin, but not to other parts of the body (locally advanced breast cancer); or to another part of the body (advanced or metastatic breast cancer).

Pabociclib is a treatment for estrogen receptor-positive (ER+) and human epidermal growth factor receptor-negative (HER2 -) breast cancer. Palbociclib is often used in combination with similar drugs such as aromatase inhibitors or Fulvestrant (Fulvestrant) to achieve better therapeutic effects. Palbociclib is a cancer growth retardant that targets cyclin-dependent kinases 4 and 6 (CDK 4 and CDK 6) on cancer cells. CDK 4 and CDK 6 are proteins that stimulate the growth and division of cancer cells. Palbociclib works by blocking these proteins. It is designed to slow or stop the progression of cancer.

It should be noted that palbociclib is not suitable for all patients and may cause some side effects, such as low blood cell counts, fatigue, nausea, etc. Therefore, it must be evaluated and guided by a doctor before use, and monitored regularly.